Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers Results following initial 3 mo
(Financial Post, 2025-10-21T11:09:02Z)